

# A Case Report of Subacute Combined Spinal Cord Degeneration Caused by Nitrous Oxide (‘Laughing Gas’) Abuse

J. Guk  
J. Valančienė  
A. Klimašauskienė

*Centre of Neurology,  
Vilnius University, Lithuania*

**Summary.** Although nitrous oxide (N<sub>2</sub>O) has long been used as an anesthetic, its use as a recreational drug has recently increased. As N<sub>2</sub>O abuse is associated with a number of adverse health effects, it has become a significant public health issue. Chronic abuse can lead to a number of neurological complications, most commonly related to functional vitamin B12 deficiency. One of the most encountered forms of N<sub>2</sub>O neurotoxicity is a subacute combined degeneration, which can cause permanent neurological damage. The medical community should therefore be aware of the increasing scale of recreational N<sub>2</sub>O exposure and the possible complications of this drug abuse. Early recognition and treatment of N<sub>2</sub>O toxicity are crucial. We present the case of an 18-year-old male who was diagnosed with subacute combined spinal cord degeneration related to N<sub>2</sub>O abuse.

**Keywords:** nitrous oxide, N<sub>2</sub>O, neurotoxicity, vitamin B12 deficiency, subacute combined degeneration.

## INTRODUCTION

Nitrous oxide (N<sub>2</sub>O), known as ‘laughing gas’, is a colorless inhalant gas that has long been used for medical and recreational purposes. N<sub>2</sub>O is currently used for medical purposes as an inhalational anesthetic, analgesic, and anxiolytic. It is also used in the food industry for whipped cream dispensers. Recently, it has gained popularity as a recreational drug due to its euphoric effect and is often inhaled using whipped cream dispensers or balloons [1–3]. In recent years, the scale of N<sub>2</sub>O use for recreational purposes has increased, particularly among young adults [3, 4]. N<sub>2</sub>O has become one of the 10 most popular psychotropic substances [5]. In the UK, for example, N<sub>2</sub>O is the second most commonly used recreational drug among young people [6, 7]. According to the Global Drug Survey 2019 (GDS2019) data from 30 countries, up to 11.9% of the re-

spondents have used N<sub>2</sub>O in the last 12 months [8]. According to the General Population Survey (GPS), nitrous oxide usage is not that widespread in Lithuania. However, in the period from 2016 to 2021, there was an increase in the inhalant use from 2.2% to 5% [9]. The ease of access and the low cost may have contributed to the high prevalence of this drug [3, 10].

N<sub>2</sub>O abuse is associated with a range of adverse health effects, but the most commonly observed toxicities are hematologic and neurologic [1, 11]. Either or both were observed in 96% of patients with N<sub>2</sub>O toxicity in a systematic review and meta-analysis by Oussalah A. et al [1]. The mechanism underlying N<sub>2</sub>O-induced toxicity is vitamin B12 inactivation. N<sub>2</sub>O causes oxidation of the cobalt ion, which is located at the center of the vitamin B12 molecule. This process results in a functional deficiency of vitamin B12 [6, 12, 13]. Vitamin B12 is a cofactor for methylmalonyl coenzyme A mutase (MMCoAM), which is responsible for the conversion of methylmalonyl-CoA to succinyl-CoA, which is essential for the metabolism of fatty acids and carbohydrates. Thus, the lack of MMCoAM activity can lead to the accumulation of methylmalonyl-CoA, which is a neurotoxic metabolite, and the subsequent decrease in succinyl-CoA disturbs the processes of

### Address:

*Jevgenija Guk  
Centre of Neurology,  
Vilnius University Hospital Santaros Clinics  
Santariškių St. 2, LT-08661 Vilnius, Lithuania  
E-mail: jevgenija.guk@santa.lt*

© Neurologijos seminarai, 2023. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License CC-BY 4.0 (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

the citric acid cycle. In addition, vitamin B12 also plays a role as a cofactor for methionine synthetase (MTR), which is responsible for the methylation of homocysteine to methionine and the simultaneous conversion of 5-methyl-tetrahydrofolate to tetrahydrofolate. These processes are necessary for deoxyribonucleic acid (DNA) synthesis, repair, and myelin production. As a consequence, functional vitamin B12 deficiency can lead to a decreased level of methionine and tetrahydrofolate, which may lead to demyelination processes and impaired DNA synthesis [2, 13–15]. At the same time, hyperhomocysteinemia due to the lack of MTR activity can lead to oxidative stress and endothelial dysfunction [16]. Thus, the disruption of B12 metabolism plays a key role in N<sub>2</sub>O-induced toxicity, the most common of which are neurological manifestations [1].

We present the case of an 18-year-old male who was diagnosed with subacute combined spinal cord degeneration related to the neurological toxicity of N<sub>2</sub>O.

## CASE PRESENTATION

An 18-year-old otherwise healthy male presented to the Neurology Department of Vilnius University Hospital (VUH) Santaros Clinics in October 2022 due to leg weakness, walking difficulties, and instability. He had sprained his right leg and developed ankle swelling while in the United Kingdom in July 2022. His local general practitioner recommended rest and he spent a month mostly confined to bed with minimal mobility and a diet consisting mainly of junk food. After a month, he noticed weakness in his left foot. When asked directly, the patient admitted to using N<sub>2</sub>O gas several times before the illness. During his time abroad, several tests were performed, including brain computed tomography (CT) and magnetic resonance imaging (MRI), which revealed no significant changes. A decreased concentration of vitamin B12 was found, and he was prescribed Hydroxycobalamin 1000 mcg by intramuscular injection every other day for 10 days. After returning to Lithuania, he underwent a nerve conduction study and electromyography in another healthcare facility, which revealed severe distal sensorimotor axonal polyneuropathy in his legs with signs of active denervation on electromyography. Motor nerves were more affected than sensory. MRI of the lumbar spine revealed primary osteochondrosis and mediolateral protrusion of the L4-5 disc without radicular compression.

Neurological examination showed intact cerebrolobar nerves, impaired proprioception in the legs with diminished vibration sensation in the feet (tested with a turning fork), and impaired joint position sensation. Examination of muscle strength showed weakness in both feet, with 1 point on the Medical Research Council (MRC) scale for dorsiflexion and 3 points for plantar flexion. Muscle strength was normal in the arms and proximal legs. The ataxic gait of moderate severity was noted when walking.




Fig. Axial T2-weighted MRI image of the cervical spinal cord demonstrating T2 hyperintensity in the dorsal spinal cord extending from C2 to C6

The patient also had hyporeflexia in the arms and areflexia in the legs. Blood tests revealed a borderline low B12 level of 124.46 pmol/L and slightly elevated creatine kinase levels (CK 867 U/L). Other blood parameters including complete blood count, renal function, electrolytes, serum protein electrophoresis, thyrotropin, ANA, ANCA, rheumatoid factor (RF), cerebrospinal fluid protein, and cell counts were within normal range. Liver enzymes were slightly elevated, so viral hepatitis was excluded after performing hepatitis B and C markers. The patient tested negative for HIV and T.pallidum infections. Fibrogastroduodenoscopy was performed to determine the cause of vitamin B12 deficiency, but no abnormalities were found.

A nerve conduction study and electromyography were repeated in our clinic and showed a distal subacute axonal sensorimotor polyneuropathy with predominantly motor nerve damage. Signs of acute denervation were present (fibrillations and positive sharp waves), and ongoing reinnervation was also noted. The parameters of the sensory nerves were slightly improved compared to the previous examination. No changes were noted in the nerve conduction studies in the arms. MRI of the cervical spine showed increased signal on T2-weighted imaging in the posterior cervical cord extending from C2 to C6, consistent with subacute combined spinal cord degeneration (Fig.).

Based on the findings, the patient was diagnosed with vitamin B12 deficiency with severe neurological complications: subacute distal sensorimotor axonal polyneuropathy with predominantly motor damage in the legs, severe paresis of both feet, and subacute combined spinal cord degeneration. In this case, there was no other explanation for the vitamin B12 deficiency other than N<sub>2</sub>O abuse. The patient was advised to continue vitamin B12 substitution, undergo rehabilitation, and was strongly encouraged to stop using N<sub>2</sub>O.

## DISCUSSION

Neurological complications due to N<sub>2</sub>O abuse are increasingly encountered by neurologists due to the exponential growth in recreational N<sub>2</sub>O use. According to the Global Drug Survey 2016 (GDS2016) data of 100,000 respondents from 50 countries, 4% of N<sub>2</sub>O users have experienced neurotoxicity [1, 5]. Although our patient was the first case of N<sub>2</sub>O-induced neurotoxicity diagnosed in the VUH Santaros Clinics and the first case report described in Lithuania, the trends are different in other countries. For example, nitrous oxide-induced subacute combined degeneration is diagnosed approximately every 9 days at the Royal London Hospital [6]. In the systematic review and meta-analysis by Oussalah A. et al., the majority of patients (57.0%) who experienced N<sub>2</sub>O toxicity were recreational users and were regularly exposed to N<sub>2</sub>O (76.0%) [1]. It should also be noted that patients with pre-existing subclinical B12 deficiency are more susceptible to the toxic effects of N<sub>2</sub>O. [6]. The most common neurological manifestations of N<sub>2</sub>O toxicity were subacute combined degeneration (28%), myelopathy (26%), and generalized demyelinating polyneuropathy (23%), while the most common neurological symptoms were paresthesia in the extremities (80%), unsteady gait or walking difficulties (58%), and weakness (43%) [1]. It is worth mentioning that N<sub>2</sub>O abuse can lead to complications potentially related to the hypercoagulable state caused by N<sub>2</sub>O-induced hyperhomocysteinemia. These complications may include ischemic stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, and cortical vein thrombosis [6, 16–20]. There are also some toxicities related to N<sub>2</sub>O use that are most likely caused by mechanisms other than B12 functional deficiency [3].

Detecting N<sub>2</sub>O toxicity can be difficult due to various reasons. First, some patients may not disclose their N<sub>2</sub>O abuse, as was observed in the case of our patient. Second, N<sub>2</sub>O neurotoxicity may be underdiagnosed, as many physicians are unaware of this condition [6]. Since there is no specific test to confirm N<sub>2</sub>O abuse, indirect tests are used to determine N<sub>2</sub>O toxicity, such as B12 metabolism disturbance. Laboratory tests may reveal an increase in mean corpuscular volume (MCV), a decrease in serum cobalamin, and an increase in homocysteine and methylmalonic acid levels [3, 21]. It is important to note that B12 deficiency may still be suspected despite the serum cobalamin level being within the normal range. In this case, elevated methylmalonic acid or homocysteine levels indicate cellular vitamin B12 deficiency [2, 21]. In patients with suspected N<sub>2</sub>O toxicity, a plasma B12 level of less than 150 pmol/L was observed in 70.7% of cases, while elevated homocysteine and methylmalonic acid levels were found in 90.3% and 93.8% of patients, respectively, according to a systematic review and meta-analysis conducted by Oussalah et al. [1].

N<sub>2</sub>O toxicity can be detected indirectly by radiological tests, particularly MRI of the spinal cord. The longer the exposure to N<sub>2</sub>O, the more obvious the changes become on

MRI images [22]. The lesions are typically hyperintense on T2 sequences and show no contrast enhancement. The shape of the lesions is usually in the form of an inverted “V”, “triangle”, or “oval” on the axial MRI [23]. Lesions typically involve more than 3 segments in the posterior columns of the spinal cord, with changes more prominent in the cervical and less often in the thoracic part of the spine [3].

The effects of N<sub>2</sub>O toxicity on peripheral nerves are generally similar to those of B12 deficiency caused by other factors, although there are some differences [24]. In cases of N<sub>2</sub>O abuse, motor axons are affected more often, as in the case we described. The lesions are typically mixed, consisting of both demyelinating and axonal damage, although our patient was diagnosed with axonal nerve damage. The damage is more pronounced in the lower extremities and depends on the dose of N<sub>2</sub>O [24, 25].

The optimal treatment for the consequences of N<sub>2</sub>O neurotoxicity remains uncertain, as there are no agreed recommendations. First, patient education plays a vital role, emphasizing the importance of complete abstinence from N<sub>2</sub>O [3]. Correcting vitamin B12 deficiency, which is strongly linked with N<sub>2</sub>O neurotoxicity, is crucial [26]. While there is no standard dosing regimen, the recommended approach involves 1 mg of hydroxocobalamin administered as an intramuscular injection daily or every other day for at least two weeks, and then continued until a plateau is reached. Patients who were B12 deficient at the onset of symptoms should receive B12 injections or oral supplementation every 3–6 months [6]. However, it should be noted that follow-up of patients may be complicated by non-adherence to treatment, as this group of patients commonly suffers from substance abuse [6]. The pathophysiological mechanisms of N<sub>2</sub>O neurotoxicity are not entirely clear, and it is believed that N<sub>2</sub>O may cause harm through other pathways besides B12 deficiency, which have not yet been established [3]. As a result, B12 supplementation does not usually result in complete symptom recovery. There are rare case reports of significant improvement after treatment with methylprednisolone or plasmapheresis [3].

In conclusion, as the prevalence of N<sub>2</sub>O abuse increases worldwide, physicians should remain vigilant about possible complications related to N<sub>2</sub>O abuse. There is a risk of N<sub>2</sub>O neurotoxicity being underdiagnosed, as most physicians are unaware of this previously unrecognized condition. Although this drug is not widely used in Lithuania, considering the tendencies of increasing prevalence in the world, a rise in cases could be expected in the future. Also, further research is needed to elucidate the precise mechanisms of N<sub>2</sub>O toxicity, to identify the potential therapeutic targets, and to develop treatment guidelines.

## References

1. Oussalah A, Julien M, Levy J, et al. Global burden related to nitrous oxide exposure in medical and recreational settings: a systematic review and individual patient data meta-analysis. *J Clin Med* 2019; 8(4): 551. <https://doi.org/10.3390/jcm8040551>

2. Parks NE. Metabolic and toxic myelopathies. *Continuum (Minneapolis)* 2021; 27(1): 143–62. <https://doi.org/10.1212/CON.0000000000000963>
3. Xiang Y, Li L, Ma X, et al. Recreational nitrous oxide abuse: prevalence, neurotoxicity, and treatment. *Neurotox Res* 2021; 39: 975–85. <https://doi.org/10.1007/s12640-021-00352-y>
4. Kaar SJ, Ferris J, Waldron J, et al. Up: the rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use. *J Psychopharmacol* 2016; 30: 395–401. <https://doi.org/10.1177/0269881116632375>
5. Winstock A, Barrett M, Ferris J, et al. Global drugs survey 2016. An overview of our key findings. *Global Drug Survey; 2016*. Available from: <https://www.drugsandalcohol.ie/25667/>
6. Paris A, Lake L, Joseph A, et al. Nitrous oxide-induced subacute combined degeneration of the cord: diagnosis and treatment. *Pract Neurol* 2023; 23(3): 222–8. <https://doi.org/10.1136/pn-2022-003631>
7. Asmussen Frank V, MacLean S, Herold MD. Nitrous oxide use among young people – new trends, policy challenges, and knowledge gaps. *Drugs Alcohol Today* 2020; 20(4): 383–92. <https://doi.org/10.1108/DAT-09-2020-0062>
8. Winstock A. Global drugs survey 2019: executive summary. *Global Drug Survey; 2019*. Available from: <https://www.drugsandalcohol.ie/30537/>
9. European Monitoring Centre for Drugs and Drug Addiction. Recreational use of nitrous oxide: a growing concern for Europe. LU: Publications Office; 2022. Available from: <https://www.drugsandalcohol.ie/37506/>
10. Thompson AG, Leite MI, Lunn MP, et al. Whippits, nitrous oxide and the dangers of legal highs. *Pract Neurol* 2015; 15: 207–9. <https://doi.org/10.1136/practneurol-2014-001071>
11. Garakani A, Jaffe RJ, Savla D, et al. Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: a systematic review of the case literature. *Am J Addict* 2016; 25(5): 358–69. <https://doi.org/10.1111/ajad.12372>
12. Kroes AC, Lindemans J, Abels J. Interaction between nitrous oxide and vitamin B12. *Ned Tijdschr Geneesk* 1985; 129(47): 2243–7.
13. Flippo TS, Holder WD. Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency. *Arch Surg* 1993; 128(12): 1391–5. <https://doi.org/10.1001/archsurg.1993.01420240099018>
14. Hathout L, El-Saden S. Nitrous oxide-induced B12 deficiency myelopathy: perspectives on the clinical biochemistry of vitamin B12. *J Neurol Sci* 2011; 301(1–2): 1–8. <https://doi.org/10.1016/j.jns.2010.10.033>
15. Ahn SC, Brown AW. Cobalamin deficiency and subacute combined degeneration after nitrous oxide anesthesia: a case report. *Arch Phys Med Rehabil* 2005; 86(1): 150–3. <https://doi.org/10.1016/j.apmr.2004.01.019>
16. Diaz-Arrastia R. Homocysteine and neurologic disease. *Arch Neurol* 2000; 57(10): 1422–7. <https://doi.org/10.1001/archneur.57.10.1422>
17. Sun W, Liao J-P, Hu Y, et al. Pulmonary embolism and deep vein thrombosis caused by nitrous oxide abuse: a case report. *World J Clin Cases* 2019; 7(23): 4057–62. <https://doi.org/10.12998/wjcc.v7.i23.4057>
18. Bajaj D, Agrawal A, Gupta S, et al. Recreational nitrous oxide abuse causing ischemic stroke in a young patient: a rare case report. *Cureus* 2018; 10(12): e3761. <https://doi.org/10.7759/cureus.3761>
19. Oomens T, Riezebos RK, Amoroso G, et al. Case report of an acute myocardial infarction after high-dose recreational nitrous oxide use: a consequence of hyperhomocysteinaemia? *Eur Heart J Case Rep* 2021; 5(2): ytaa557. <https://doi.org/10.1093/ehjcr/ytaa557>
20. Liu M, Zhang J, Bu B. Isolated cortical vein thrombosis after nitrous oxide use in a young woman: a case report. *BMC Neurol* 2020; 20: 378. <https://doi.org/10.1186/s12883-020-01961-4>
21. Devalia V, Hamilton MS, Molloy AM, British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. *Br J Haematol* 2014; 166(4): 496–513. <https://doi.org/10.1111/bjh.12959>
22. Tuan TA, Minh Duc N, Sy TV, et al. The clinical and subclinical features of spinal cord injury on magnetic resonance imaging of patients with N<sub>2</sub>O intoxication. *Neurol Int* 2020; 12(2): 8652. <https://doi.org/10.4081/ni.2020.8652>
23. Zheng D, Ba F, Bi G, et al. The sharp rise of neurological disorders associated with recreational nitrous oxide use in China: a single-center experience and a brief review of Chinese literature. *J Neurol* 2020; 267: 422–9. <https://doi.org/10.1007/s00415-019-09600-w>
24. Tani J, Weng H-Y, Chen H-J, et al. Elucidating unique axonal dysfunction between nitrous oxide abuse and vitamin B12 deficiency. *Front Neurol* 2019; 10: 704. <https://doi.org/10.3389/fneur.2019.00704>
25. Winstock AR, Ferris JA. Nitrous oxide causes peripheral neuropathy in a dose dependent manner among recreational users. *J Psychopharmacol* 2020; 34(2): 229–36. <https://doi.org/10.1177/0269881119882532>
26. Massey TH, Pickersgill TT, J Peall K. Nitrous oxide misuse and vitamin B12 deficiency. *BMJ Case Rep* 2016; 2016: bcr2016215728. <https://doi.org/10.1136/bcr-2016-215728>

J. Guk, J. Valančienė, A. Klimašauskienė

**POŪMĖS KOMBINUOTOS NUGAROS SMEGENŲ DEGENERACIJOS, SUKELTOS DIAZOTO MONOKSIDO („LINKSMINANČIŲ DUJŲ“) VARTOJIMO, KLINIKINIO ATVEJO APRAŠYMAS**

**Santrauka**

Diazoto monoksidas (N<sub>2</sub>O) yra inhaliuojamos dujos, jau ilgą laiką naudojamos anestezijai, tačiau pastaraisiais metais šios medžiagos vartojimas rekreaciniais tikslais tapo ypač populiarus. Piktnaudžiavimas N<sub>2</sub>O dujomis yra susijęs su įvairiais nepageidaujamais reiškiniais, todėl tai tampa reikšminga visuomenės sveikatos problema. Lėtinis piktnaudžiavimas šia medžiaga gali sukelti įvairių neurologinių komplikacijų, dažniausiai susijusių su funkcinė vitamino B12 stoka. Viena iš dažniausių N<sub>2</sub>O neurotoksiškumo formų – poūmė kombinuota degeneracija, kuri gali lemti permanentinį neurologinį pažeidimą. Taigi, medicinos bendruomenė turėtų žinoti apie augantį rekreacinio N<sub>2</sub>O vartojimo mastą ir galimas to komplikacijas. Tinkamas N<sub>2</sub>O toksiškumo išraiškų atpažinimas ir gydymas yra būtini. Šiame straipsnyje pristatomas 18 metų vyro, kuriam buvo diagnozuota poūmė kombinuota nugaros smegenų degeneracija, susijusi su piktnaudžiavimu N<sub>2</sub>O, atvejis.

**Raktažodžiai:** diazoto monoksidas, N<sub>2</sub>O, neurotoksiškumas, vitamino B12 stoka, poūmė kombinuota degeneracija.

Gauta: 2023 05 22  
 Priimta spaudai: 2023 06 01